Skip to main content
OpenTrials
Completed

NCT Number: NCT02250755

MRI Perfusion on T1 and T2 Brain Lesion(s)

This study therefore aims to assess current treatment recommended by scientific societies [ 6-13 ] , brain MRI with injection of contrast for the diagnosis and monitoring of brain metastases . The recommended dose of this examination gadolinium is from 0.1 to 0.3 mmol / kg [ 14 ] . Sequences infusion different from one center to the other made : some use the infusion T1, other infusion T2 * . No recommendation establishes whether it is preferable to use one or the other of these sequences.

No examination is added for the purposes of protocol. Indications for MRI and the number and timing of MRI checks under this protocol are consistent with what is done in practice . The used type of gadolinium and the injected dose will be identical for both sequences infusion . The assessment shall not in any case the contrast but the interpretation of the sequence itself. Special procedures monitoring implemented embodiment correspond to the two sequences instead of infusion (one of T1-weighted and T2 * in the other ) , in the original MRI and MRI of the first control , in order to compare their effectiveness

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Carcinoma Metastatic to the Brain Brain Diseases Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hopital Salengro CHRU de Lille

Lille, 59037, France

About this study

Eligibility criteria:

  • Major Patients
  • Addressed MRI for initial assessment of brain metastases
  • At a suspicion of one or more brain metastases in the brain scanner routine screening
  • Follow for lung cancer histologically documented
  • In the Thoracic Oncology Service Professor Lafitte (contact: Dr Cortot)
  • To whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered
  • Be socially insured

Main Outcomes measures:

Comparing the area under the ROC curve of different parameters evaluated in T1 and T2 * perfusion during the initial assessment for the diagnosis of maximal tumor response evaluated at 1 year

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Major Patients
  • Addressed to MRI for initial assessment of brain metastases
  • At a suspicion of one or more brain metastases in the brain scanner routine screening
  • Followed for lung cancer histologically documented in the Thoracic Oncology Service of Professor Lafitte (contact: Dr Cortot)
  • To whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered
  • Be socially insured-

Exclusion criteria

  • Absolute contraindication to MRI (pacemaker, implantable pacemaker, metallic foreign body intraorbital)
  • Patients minors under guardianship / curatorship
  • Patients with impaired judgment skills or unable to receive information
  • Pregnant Women
  • Patients for which lesions are not compatible with lung metastases
  • Patients with brain metastases or already known and explored MRI
  • Patients for whom treatment by surgical excision of brain metastases is considered

Treatment and study plan

MRI T1 T2 sequences

Other

MRI

Primary outcomes

  1. Comparing different parameters evaluated in T1 and T2 * perfusion

    Time frame: 3 years

    Comparing the area under the ROC curve of different parameters evaluated in T1 and T2 * perfusion during the initial assessment for the diagnosis of maximal tumor

Secondary outcomes

  1. Evaluation tumor response

    Time frame: 1 year

    Comparison of the area under the ROC curve of the change in the first control of the various parameters measured in T1 and T2 * infusion, for the diagnosis of maximum tumor response evaluated at 1 year

  2. Radiological progression-free survival

    Time frame: 1 year

    Comparison of the ability of the two sequences to predict infusion:

  3. Survival without neurological signs

    Time frame: 1 year

    Comparison of the ability of the two sequences to predict infusion:

Sponsors and collaborators

Lead sponsor

University Hospital, Lille

Other

Registry information

Official study title

Comparison of MRI Sequences T1 and T2 * Cerebral Perfusion to Aid in the Diagnosis and Evaluation of Brain Therapeutic Response With Chemotherapy or Targeted Therapy(s) Lesion(s) in Patients Treated and Followed for a Pulmonary Neoplasia

Acronym: METAPERF

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Sep 26, 2014
Registry last updated
Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.